DBV Technologies (DBVT) Non-Current Assets (2015 - 2026)
DBV Technologies (DBVT) posted Non-Current Assets of $21.3 million for Q2 2026, up 8.12% sequentially from $19.7 million in Q1 2026, and down 4.0% YoY from $22.2 million in Q2 2025.
DBV Technologies (DBVT) Non-Current Assets (2015 - 2026) Analysis & Trends
DBV Technologies has reported Non-Current Assets for 12 years, with the latest figure at $21.3 million in Q2 2026.
- Quarterly Non-Current Assets fell 4.0% year-over-year to $21.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $21.3 million (down 4.0% YoY) and the FY2025 annual result came in at $20.8 million, down 2.21% from the prior year.
- Non-Current Assets improved to $21.3 million in Q2 2026 per DBVT's latest filing, from $19.7 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $27.1 million in Q1 2022 and troughed at $19.7 million in Q1 2026.
- A 5-year average of $22.8 million and a median of $22.3 million in 2022 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2024: Non-Current Assets slumped 63.11% in 2022, then rose 18.44% in 2024.
- Over 5 years, Non-Current Assets stood at $23.4 million in 2022, then advanced by 2.67% to $24.1 million in 2023, then fell by 11.63% to $21.3 million in 2024, then slipped by 2.21% to $20.8 million in 2025, then rose by 2.4% to $21.3 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $21.3 million, $19.7 million, and $20.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | DBV Technologies | 6.08 Bn | 5.90 Bn | - | 21.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.30 Mn |
| Mar 31, 2026 | 19.70 Mn |
| Dec 31, 2025 | 20.80 Mn |
| Sep 30, 2025 | 21.61 Mn |
| Jun 30, 2025 | 22.19 Mn |
| Mar 31, 2025 | 21.41 Mn |
| Dec 31, 2024 | 21.27 Mn |
| Sep 30, 2024 | 24.30 Mn |
| Jun 30, 2024 | 24.23 Mn |
| Mar 31, 2024 | 26.33 Mn |
| Dec 31, 2023 | 24.07 Mn |
| Sep 30, 2023 | 20.51 Mn |
| Jun 30, 2023 | 21.98 Mn |
| Mar 31, 2023 | 22.69 Mn |
| Dec 31, 2022 | 23.44 Mn |
| Sep 30, 2022 | 22.42 Mn |
| Jun 30, 2022 | 25.03 Mn |
| Mar 31, 2022 | 27.14 Mn |
| Dec 31, 2021 | 32.34 Mn |
| Sep 30, 2021 | 60.79 Mn |